The corona vaccination of the duo Pfizer and Biontech brought the American group more sales in the third quarter.

But the pharmaceutical manufacturer Pfizer was also able to make further gains outside of the business with the vaccine Comirnaty.

The management around CEO Albert Bourla raised its annual targets again.

Pfizer stock rose 2.7 percent in pre-trading in New York.

The Biontech papers also grew.

In the third quarter, Pfizer more than doubled sales to $ 24.1 billion. The vaccination business alone contributed around two thirds of this with 14.6 billion. However, Pfizer also recorded significant growth in clinical nutrition and cancer drugs. However, the classic core business fell short of expectations, wrote analyst Chris Schott from the US bank JPMorgan in an initial reaction. The bottom line was a profit of $ 8.1 billion. In the same quarter of the previous year, i.e. before the start of the corona vaccination campaign, it was just under 1.5 billion.

According to the new forecast, sales in 2021 should almost double compared to the previous year to 81 to 82 billion dollars (up to 70.7 billion euros).

Pfizer expects the vaccine to make an even greater contribution than before, as further supply agreements have now been made with buyer countries.

Several lines of business are doing better than expected

Comirnaty should therefore contribute around 36 billion dollars instead of the previously forecast around 33.5 billion.

But the rest of the business should also bring more than previously expected.

The earnings per share (EPS) adjusted for one-off effects should increase more strongly than previously expected by the Group.

Pfizer plans to produce a total of three billion doses of its vaccine by the end of the year, of which 2.3 billion doses should be shipped. That number is covered by supply agreements in and outside the United States, it said. Pfizer is also on track with its goal of delivering at least two billion doses to emerging and developing countries by the end of 2022. Around one billion of these cans are to be processed at cost via a US program.

The corona vaccination by Pfizer and Biontech, which is based on the relatively new messenger RNA technology (mRNA), is now approved for more and more people.

Just a few days ago, the partners in the USA were the first vaccine provider to receive emergency approval for children between the ages of five and eleven.

The United States also secured millions of doses for children under five, but there has not yet been a green light for this age group.

Pfizer and Biontech should also be given a boost by the booster vaccinations.